抗生素与癌症免疫治疗结局:116个队列、近9.8万例患者的更新荟萃分析
Antibiotics and outcomes of cancer immunotherapy: An updated meta-analysis and clinical applications

一项发表于 Cancer Cell 的更新荟萃分析汇总116个队列、近9.8万例接受免疫检查点抑制剂(ICI)治疗的患者,发现抗生素暴露与更差的总生存期和无进展生存期显著相关。作者同时提出抗菌药物管理和基于微生物组的策略,用于预防和修复抗生素导致的菌群失调。
原文摘要
出版方登记 · OpenAlexThe gut microbiome is a modifiable determinant of response to immune checkpoint inhibitors (ICI), positioning antibiotic exposure as a critical yet under-recognized risk factor for worse survival outcomes in immuno-oncology. As nearly 30% of ICI-treated patients receive antibiotics and indications of cancer immunotherapy are expanding, this issue represents a global challenge in oncology. Here, we paint an updated and comprehensive landscape of antibiotic exposure in immuno-oncology, provide actionable clinical recommendations, and envision future avenues for improvement. First, we describe the biological mechanisms by which antibiotic-induced dysbiosis contributes to ICI resistance. Next, through an updated meta-analysis of 116 cohorts and 97,850 cancer patients treated with ICI, we found a significant association between antibiotic exposure and survival outcomes (overall survival, hazard ratio [HR]: 1.49, 95% confidence interval [CI]: 1.34-1.65; progression-free survival, HR: 1.44, 95% CI: 1.31-1.58). Finally, we discuss antibiotics stewardship and microbiome-centered strategies to prevent, diagnose, and/or repair dysbiosis.
页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文
这项纳入116个队列、近9.8万例患者的更新荟萃分析量化了抗生素暴露与ICI生存结局的关联,可供临床权衡抗生素使用。
来源:Cancer Cell · cell.com